Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universitë De Bordeaux

Université D'angers

Centre Hospitalier Universitaire De Bordeaux

Centre Hospitalier Universitaire D'angers

Cecile Contin-bordes

Patrick Blanco

Pascale Jeannin

Yahsou Delmas

Yves Delneste

Jean-francois Augusto

Celine Beauvillain

The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount Lof clusterin, and 2) comparing the amount Lmeasured in step 1) with an amount Lof clusterin by calculating the score S1=L/L, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

Clusterin for use in the treatment of thrombotic microangiopathies

Growing community of inventors

MERIGNAC, France

Cecile Contin-bordes